|
Funding source
| |
|
governmental
|
12 (18)
|
|
private not for profit
|
3 (4)
|
|
private for profit
|
41 (61)
|
|
Private for profit plus other source
|
4 (6)
|
|
Not funded
|
3 (4)
|
|
Not reported
|
14 (21)
|
|
Publication language
| |
|
English
|
67 (100)
|
|
Sample size
| |
|
Median (Q1-Q3)
|
156 (74-355)
|
|
n <200
|
39 (58)
|
|
n ≥200
|
28 (42)
|
|
Type of cancer
| |
|
Participants with different cancer types
|
47 (70)
|
|
Cancer type not reported
|
5 (7)
|
|
All participants with same cancer type
|
15 (22)
|
|
Lung
|
5 (33)
|
|
Colorectal
|
2 (13)
|
|
Gynecologic
|
2 (13)
|
|
Prostate
|
1 (7)
|
|
Breast
|
1 (7)
|
|
Pancreatic
|
1 (7)
|
|
Hematological
|
2 (13)
|
|
Hematological and solid tumors
|
1 (6)
|
|
Cancer as subgroup of the study
|
27 (40)
|
|
Intervention
| |
|
LMWH
|
53 (79)
|
|
UFH
|
33 (49)
|
|
Vitamin K antagonist
|
20 (30)
|
|
Direct thrombin inhibitors
|
5 (7)
|
|
Fondaparinux
|
3 (4)
|
|
Comparator
| |
|
Active treatment
|
47 (70)
|
|
Placebo
|
9 (13)
|
|
No treatment
|
11 (17)
|
